ANDA 90516, held by Aurobindo Pharma USA. Nabumetone.
As of Nov 15, 2026, ANDA 90516 (Nabumetone), held by Aurobindo Pharma USA, was first approved by FDA on Jul 12, 2010, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 12, 2010 | Original application | Approved | None posted |
| Nabumetone500MG · tablet;oral | Nabumetone | Discontinued |
| Nabumetone750MG · tablet;oral | Nabumetone | Discontinued |
| Nov 21, 2024 | Supplement 5Labeling · Standard review | Approved | None posted |
| Apr 28, 2021 | Supplement 4Labeling · Standard review | Approved | None posted |
| May 9, 2016 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jul 12, 2010 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters